This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read INmune Bio’s 8K filing here.
About INmune Bio
INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.
Featured Stories
- Five stocks we like better than INmune Bio
- What Are Dividend Contenders? Investing in Dividend Contenders
- Inflation Risk Rising, Key Trades Investors Are Making Now
- What is a Dividend King?
- 3 Oil Stocks to Watch Before Earnings Come Out
- Insider Buying Explained: What Investors Need to Know
- Is American Express Stock’s Sell-the-News Reaction a Buying Opp?
